Co-evolution: Immune to defeat
Organisms that grow in close contact with one another often co-evolve. This is particularly evident in pathogens and their hosts, with each always needing to stay one small step ahead of the other in order to survive. This evolutionary competition has given rise to the systems of immune molecules that hosts use to recognize and neutralize invading pathogens, and also to the effector molecules that pathogens use to survive attack by the immune system. A prime example of this can be seen in the interactions between a class of enzymes called the immune-related GTPases (IRG proteins) and the pathogens that they recognize and destroy (Kim et al., 2012). It is known that IRG proteins work by assembling on the surface of the vacuoles within which the pathogens replicate, but the details of this mechanism are poorly understood.
Now, in eLife, Jonathan Howard of the University of Cologne and colleagues present striking evidence that the co-evolution of IRG proteins with Toxoplasma gondii—the parasite that causes toxoplasmosis—has been an important driving force in the functional evolution of the IRG system (Lilue et al., 2013). Howard and colleagues—including Jingtao Lilue as first author, Urs Muller and Tobias Steinfeldt—found that mice derived from wild mice were resistant to strains of the parasite that were lethal to laboratory mice. Remarkably, they demonstrated that this resistance was due to genetic variation in one particular form of IRG protein, named Irgb2-b1: they found that certain alleles of Irgb2-b1 appeared to inhibit the activity of the effector molecules secreted by the parasite, which themselves have evolved to inactivate the IRG system.
As it enters a new host cell, Toxoplasma secretes an active kinase called ROP18 and a diverse family of pseudokinases, called ROP5. The ROP5 pseudokinases appear to sequester the IRG proteins and then present them for phosphorylation by ROP18 (Fleckenstein et al., 2012). The process of phosphorylation inactivates the IRG proteins, which prevents them from assembling on the surface of the vacuole. This, in turn, allows the parasites to replicate (Figure 1; Steinfeldt et al., 2010; Fentress et al., 2010). There are considerable differences in the virulence (to mice) of the major strains of Toxoplasma, and genetic variations in ROP5 and ROP18 can explain almost all of these differences (Saeij et al., 2006; Taylor et al., 2006; Behnke et al., 2011; Reese et al., 2011). This highlights the importance of the IRG system in the control of Toxoplasma infection in mice, and the pressure that competition with this system has placed on the parasite.
As is typical of genes under strong selective pressure, the IRG genes differ both in copy number and in coding sequence in closely related species and even, as described by Lilue et al., among individuals within the same species. Previously the different forms of an IRG protein have been grouped into two distinct functional classes: effector IRG proteins that destroy the vacuoles inside which the pathogens replicate, and regulatory IRGs that are thought to inhibit premature activation of the system (Hunn et al., 2011). However, Irgb2-b1—the form of the protein identified by Lilue et al.—appears to belong to a third class of IRG proteins that recognize a particular pathogen effector rather than the pathogen itself. They found that Irgb2-b1 only attached itself to Toxoplasma vacuoles that were already coated with ROP5. Moreover, Irgb2-b1 loading appeared to block the activity of the ROP5 and ROP18 proteins. This left the effector IRG proteins free to assemble on the surface of the vacuole, thus leading to the destruction of the parasite (Figure 1). Strikingly, mice that carried the protective allele of Irgb2-b1 were able to survive acute infection with a highly virulent strain of the parasite, whereas infection by just one parasite of the same strain would kill a laboratory mouse.
Toxoplasma is also a survivor—as the acute infection ends, the parasite switches to a slow-growing form that becomes enclosed within cysts in the brain and muscle of the host, as was the case with the wild mice studied by Lilue et al. When a host is killed and eaten by a carnivore, the parasite switches back to a fast growing stage to infect its new host. Because strains of the parasite that secrete the virulent versions of both ROP5 and ROP18 are able to completely defeat the IRG system in laboratory mice, it was thought that these strains could not have co-evolved with mice, because the death of the host can be an evolutionary dead-end for a pathogen. The fact that Irgb2-b1 derived from wild mice represents a specific countermeasure to the parasite effectors provides a strong argument for co-evolution. The work of Lilue, Muller, Steinfeldt and Howard thus reminds us to look beyond lab-adapted organisms and examine biology in the wild to discover its full diversity.
References
-
Virulence differences in Toxoplasma mediated by amplification of a family of polymorphic pseudokinasesProc Natl Acad Sci USA 108:9631–9636.https://doi.org/10.1073/pnas.1015338108
-
IFN-inducible GTPases in host cell defenseCell Host Microbe 12:432–444.https://doi.org/10.1016/j.chom.2012.09.007
-
Polymorphic family of injected pseudokinases is paramount in Toxoplasma virulenceProc Natl Acad Sci USA 108:9625–9630.https://doi.org/10.1073/pnas.1015980108
Article and author information
Author details
Publication history
- Version of Record published: October 29, 2013 (version 1)
Copyright
© 2013, Reese
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 555
- Page views
-
- 50
- Downloads
-
- 0
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Microbiology and Infectious Disease
The mitochondrial genomes of apicomplexans comprise merely three protein-coding genes, alongside a set of thirty to forty genes encoding small RNAs (sRNAs), many of which exhibit homologies to rRNA from E. coli. The expression status and integration of these short RNAs into ribosomes remains unclear and direct evidence for active ribosomes within apicomplexan mitochondria is still lacking. In this study, we conducted small RNA sequencing on the apicomplexan Toxoplasma gondii to investigate the occurrence and function of mitochondrial sRNAs. To enhance the analysis of sRNA sequencing outcomes, we also re-sequenced the T. gondii mitochondrial genome using an improved organelle enrichment protocol and Nanopore sequencing. It has been established previously that the T. gondii genome comprises 21 sequence blocks that undergo recombination among themselves but that their order is not entirely random. The enhanced coverage of the mitochondrial genome allowed us to characterize block combinations at increased resolution. Employing this refined genome for sRNA mapping, we find that many small RNAs originated from the junction sites between protein-coding blocks and rRNA sequence blocks. Surprisingly, such block border sRNAs were incorporated into polysomes together with canonical rRNA fragments and mRNAs. In conclusion, apicomplexan ribosomes are active within polysomes and are indeed assembled through the integration of sRNAs, including previously undetected sRNAs with merged mRNA-rRNA sequences. Our findings lead to the hypothesis that T. gondii’s block-based genome organization enables the dual utilization of mitochondrial sequences as both messenger RNAs and ribosomal RNAs, potentially establishing a link between the regulation of rRNA and mRNA expression.
-
- Medicine
- Microbiology and Infectious Disease
Hepatic ischemia/reperfusion injury (HIRI) is a common and inevitable factor leading to poor prognosis in various liver diseases, making the outcomes of current treatments in clinic unsatisfactory. Metformin has been demonstrated to be beneficial to alleviate HIRI in recent studies, however, the underpinning mechanism remains unclear. In this study, we found metformin mitigates HIRI-induced ferroptosis through reshaped gut microbiota in mice, which was confirmed by the results of fecal microbiota transplantation treatment but showed the elimination of the beneficial effects when gut bacteria were depleted using antibiotics. Detailedly, through 16S rRNA and metagenomic sequencing, we identified that the metformin-reshaped microbiota was characterized by the increase of gamma-aminobutyric acid (GABA) producing bacteria. This increase was further confirmed by the elevation of GABA synthesis key enzymes, glutamic acid decarboxylase and putrescine aminotransferase, in gut microbes of metformin-treated mice and healthy volunteers. Furthermore, the benefit of GABA against HIRI-induced ferroptosis was demonstrated in GABA-treated mice. Collectively, our data indicate that metformin can mitigate HIRI-induced ferroptosis by reshaped gut microbiota, with GABA identified as a key metabolite.